MORRISVILLE, N.C. , April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) announced today that Dr. Roger Jeffs , Chief Executive Officer, and Micheal Kaseta , Chief Operating Officer and Chief Financial Officer, will provide an overview and update on the

On March 28 , Judge Andrews removed the injunction issued in the Original Hatch Waxman Litigation On March 29 , Judge Bates denied United Therapeutics’ motion for temporary restraining order and preliminary injunction in separate litigation filed by United Therapeutics against the FDA On March 31 ,

Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approval Federal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalid Advancing industry leading portfolio for inhaled treprostinil with YUTREPIA and

MORRISVILLE, N.C. , March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024 . The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a

MORRISVILLE, N.C. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) today announced that the Company will present data from the L606 clinical program at the Pulmonary Vascular Research Institute (PVRI) 2024 Annual Congress to be held January 31

MORRISVILLE, N.C. , Jan. 25, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) provided an update on its review of the New Drug Application (NDA) for YUTREPIA™ (treprostinil) inhalation powder to treat

MORRISVILLE, N.C. , Jan. 19, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) announced today updates and promotions to its operations leadership in advance of the potential approval and launch of YUTREPIA™ (treprostinil) inhalation powder.

Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal Circuit Requests declaration that ‘327 patent is not infringed, is invalid and is unenforceable Files counterclaims asserting United Therapeutics failed to properly

Enrolled first PH-ILD patient in the open-label ASCENT study of YUTREPIA Confirmed with FDA that a single pivotal efficacy trial with L606 will support PAH and PH-ILD indications MORRISVILLE, N.C. , Jan. 05, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company)

Agreed to $75.0 million sale of common stock to fund affiliated with Patient Square Capital in a private placement Additional advance of $25.0 million from HealthCare Royalty under current financing agreement MORRISVILLE, N.C. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA)